Aprogen Pharmaceuticals Inc (003060) - Net Assets
Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has net assets worth ₩315.16 Billion KRW (≈ $213.58 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩603.42 Billion ≈ $408.93 Million USD) and total liabilities (₩288.27 Billion ≈ $195.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Aprogen Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩315.16 Billion |
| % of Total Assets | 52.23% |
| Annual Growth Rate | 19.81% |
| 5-Year Change | -36.71% |
| 10-Year Change | 458.99% |
| Growth Volatility | 44.59 |
Aprogen Pharmaceuticals Inc - Net Assets Trend (2009–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore 003060 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Aprogen Pharmaceuticals Inc (2009–2024)
The table below shows the annual net assets of Aprogen Pharmaceuticals Inc from 2009 to 2024. For live valuation and market cap data, see 003060 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩378.69 Billion ≈ $256.63 Million |
+2.71% |
| 2023-12-31 | ₩368.69 Billion ≈ $249.86 Million |
-27.77% |
| 2022-12-31 | ₩510.41 Billion ≈ $345.90 Million |
-14.53% |
| 2021-12-31 | ₩597.18 Billion ≈ $404.70 Million |
-0.20% |
| 2020-12-31 | ₩598.36 Billion ≈ $405.50 Million |
+72.12% |
| 2019-12-31 | ₩347.64 Billion ≈ $235.59 Million |
+130.97% |
| 2018-12-31 | ₩150.51 Billion ≈ $102.00 Million |
+93.31% |
| 2017-12-31 | ₩77.86 Billion ≈ $52.77 Million |
-0.33% |
| 2016-12-31 | ₩78.12 Billion ≈ $52.94 Million |
+15.32% |
| 2015-12-31 | ₩67.75 Billion ≈ $45.91 Million |
+9.07% |
| 2014-12-31 | ₩62.11 Billion ≈ $42.09 Million |
+9.84% |
| 2013-12-31 | ₩56.55 Billion ≈ $38.32 Million |
-17.46% |
| 2012-12-31 | ₩68.51 Billion ≈ $46.43 Million |
-6.78% |
| 2011-12-31 | ₩73.49 Billion ≈ $49.80 Million |
+71.68% |
| 2010-12-31 | ₩42.81 Billion ≈ $29.01 Million |
+3.46% |
| 2010-09-30 | ₩41.38 Billion ≈ $28.04 Million |
+64.35% |
| 2009-12-31 | ₩25.18 Billion ≈ $17.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aprogen Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 171293.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩617.69 Billion | 163.20% |
| Total Equity | ₩378.49 Billion | 100.00% |
Aprogen Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GHCL Limited
NSE:GHCL
|
$503.88 Million |
|
Jilin Jinguan Electric Co Ltd Class A
SHE:300510
|
$504.43 Million |
|
Titan International Inc
NYSE:TWI
|
$504.51 Million |
|
C&C Group PLC
F:GCC
|
$504.62 Million |
|
ForFarmers NV
AS:FFARM
|
$503.79 Million |
|
Jereissati Participações S.A.
SA:IGTI3
|
$503.75 Million |
|
Youngy Health Co Ltd
SHE:300247
|
$503.57 Million |
|
Lutian Machinery Co Ltd
SHG:605259
|
$503.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aprogen Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 368,691,477,730 to 378,491,355,950, a change of 9,799,878,220 (2.7%).
- Net loss of 104,978,891,930 reduced equity.
- Share repurchases of 21,723,670 reduced equity.
- New share issuances of 115,758,613,450 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-104.98 Billion | -27.74% |
| Share Repurchases | ₩21.72 Million | -0.01% |
| Share Issuances | ₩115.76 Billion | +30.58% |
| Other Changes | ₩-958.12 Million | -0.25% |
| Total Change | ₩- | 2.66% |
Book Value vs Market Value Analysis
This analysis compares Aprogen Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.11x to 1.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩615.89 | ₩3763.12 | x |
| 2018-12-31 | ₩933.93 | ₩3763.12 | x |
| 2019-12-31 | ₩897.96 | ₩3763.12 | x |
| 2020-12-31 | ₩1268.02 | ₩3763.12 | x |
| 2021-12-31 | ₩1274.40 | ₩3763.12 | x |
| 2022-12-31 | ₩5533.60 | ₩3763.12 | x |
| 2023-12-31 | ₩560.72 | ₩3763.12 | x |
| 2024-12-31 | ₩1915.71 | ₩3763.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aprogen Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -155.81%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.56x
- Recent ROE (-27.74%) is below the historical average (-10.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -37.07% | -70.58% | 0.38x | 1.39x | ₩-26.48 Billion |
| 2014 | -6.24% | -11.75% | 0.39x | 1.36x | ₩-10.12 Billion |
| 2015 | 3.99% | 6.85% | 0.47x | 1.23x | ₩-4.16 Billion |
| 2016 | -4.87% | -8.88% | 0.34x | 1.60x | ₩-11.96 Billion |
| 2017 | -21.02% | -35.50% | 0.29x | 2.03x | ₩-24.15 Billion |
| 2018 | -0.81% | -2.68% | 0.21x | 1.44x | ₩-16.27 Billion |
| 2019 | -3.38% | -16.33% | 0.14x | 1.48x | ₩-32.95 Billion |
| 2020 | 2.23% | 21.10% | 0.09x | 1.22x | ₩-39.29 Billion |
| 2021 | 1.60% | 14.35% | 0.09x | 1.21x | ₩-42.69 Billion |
| 2022 | 2.96% | 19.39% | 0.10x | 1.60x | ₩-30.01 Billion |
| 2023 | -32.08% | -135.38% | 0.15x | 1.60x | ₩-155.14 Billion |
| 2024 | -27.74% | -155.81% | 0.11x | 1.56x | ₩-142.83 Billion |
Industry Comparison
This section compares Aprogen Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aprogen Pharmaceuticals Inc (003060) | ₩315.16 Billion | -37.07% | 0.91x | $503.85 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.